Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Rein Therapeutics Inc. (RNTX) had Return on Tangible Equity of 20.00% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-15.73M |
|
-- |
|
-- |
|
$16.28M |
|
$-16.28M |
|
$0.54M |
|
$-15.73M |
|
$-15.73M |
|
$-15.73M |
|
$-15.73M |
|
$-15.73M |
|
$-15.73M |
|
$-16.28M |
|
$-16.12M |
|
4.60M |
|
4.60M |
|
$-3.42 |
|
$-3.42 |
|
| Balance Sheet Financials | |
$18.27M |
|
$0.02M |
|
$87.74M |
|
$106.01M |
|
$4.38M |
|
-- |
|
$94.74M |
|
$99.12M |
|
$6.89M |
|
$-78.64M |
|
$6.89M |
|
4.88M |
|
| Cash Flow Statement Financials | |
$-19.81M |
|
$16.20M |
|
$15.79M |
|
$5.22M |
|
$17.34M |
|
$12.12M |
|
$1.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.17 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-228.43% |
|
|
Return on Tangible Equity |
20.00% |
-14.84% |
|
-228.43% |
|
$1.41 |
|
$-4.30 |
|
$-4.31 |
|